Ozempic. (TT / NTB Scanpix)

Analytiker: Bipacksedeln kan lyfta Novo Nordisk

Det var väntat att Novo Nordisks diabetesläkemedel Ozempic skulle godkännas av den amerikanska läkemedelsmyndigheten FDA. Men en positiv utformning av texten på läkemedlets bipacksedel kan likväl ge aktien ett lyft på onsdagen, säger Sydbanks analytiker Søren Løntoft Hansen till Ritzau.

Hansen spår att Ozempic nu gradvis kommer att bli en allt större del av Novo Nordisk försäljning.

– Enligt min värdering kommer detta läkemedel att inom fem till tio år att utgöra ryggraden i koncernens omsättning och intjäning, säger han till Ritzau.

Läs också

bakgrund
 
Novo Nordisk
Wikipedia (en)
Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (75%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services. Key products include diabetes care medications and devices. Novo Nordisk is also involved with hemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza. Novo Nordisk employs more than 40,000 people globally, and markets its products in 180 countries. The corporation was created in 1989 through a merger of two Danish companies which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among 100 best companies to work for in 2010 by Fortune. In January 2012, Novo Nordisk was named as the most sustainable company in the world by the business magazine Corporate Knights while spin-off company Novozymes was named fourth. Novo Nordisk was ranked 72nd on “Fortune’s 100 Best Companies to Work For®” list within the U.S. state of New Jersey as of January 2014.
Omni är politiskt obundna och oberoende. Vi strävar efter att ge fler perspektiv på nyheterna. Har du frågor eller synpunkter kring vår rapportering? Kontakta redaktionen